Understanding thiopurine methyltransferase polymorphisms for the targeted treatment of hematologic malignancies.
Animals
Antimetabolites, Antineoplastic
/ administration & dosage
Genotype
Humans
Mercaptopurine
/ administration & dosage
Methyltransferases
/ genetics
Molecular Targeted Therapy
Polymorphism, Genetic
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/ drug therapy
Thioguanine
/ administration & dosage
Acute lymphoblastic leukemia
TPMT
genetic polymorphisms
myelosuppression
sinusoidal obstruction syndrome
thiopurines
Journal
Expert opinion on drug metabolism & toxicology
ISSN: 1744-7607
Titre abrégé: Expert Opin Drug Metab Toxicol
Pays: England
ID NLM: 101228422
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
pubmed:
29
8
2021
medline:
5
11
2021
entrez:
28
8
2021
Statut:
ppublish
Résumé
Thiopurine methyltransferase (TPMT) catalyzes the S-methylation of thiopurines (mercaptopurine (MP) and tioguanine (TG)), chemotherapeutic agents used in the treatment of acute lymphoblastic leukemia (ALL). Polymorphisms in This review gives an overview on To titrate thiopurines safely and effectively, achieve the right degree of lymphotoxic effect and avoid excessive myelosuppression, the optimal management will combine a preemptive
Identifiants
pubmed: 34452592
doi: 10.1080/17425255.2021.1974398
doi:
Substances chimiques
Antimetabolites, Antineoplastic
0
Mercaptopurine
E7WED276I5
Methyltransferases
EC 2.1.1.-
thiopurine methyltransferase
EC 2.1.1.67
Thioguanine
FTK8U1GZNX
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM